

Data Powered Pathology



Precision Pathology for Better Patient Outcomes

Reveal Biosciences offers **Pathology Intelligence™ solutions** to advance preclinical and clinical research using AI to develop digital assays via the **cloud-based imageDx™ pathology platform**.


Generate quantitative pathology endpoints by combining our digital assays with our **high-quality preclinical histopathology services** (FFPE and frozen samples):

- Off-the-shelf and customized single-plex and multiplex IF, IHC and ISH assays
- High-resolution whole slide imaging
- Pathology review with board-certified veterinary and anatomic pathologists

**COMBINING CUTTING-EDGE AI WITH TRADITIONAL HISTOPATHOLOGY
TO TRANSFORM TISSUE BIOLOGY INTO ACTIONABLE DATA**

AI-based digital assays on the imageDx platform for preclinical, clinical trials and decision support

- | | |
|---|---|
| <ul style="list-style-type: none">▪ Increased accuracy over traditional images▪ Integrated AI-powered image QC
(high-level artifact detection and color profiling) | <ul style="list-style-type: none">▪ Vendor agnostic image format▪ Unlimited parallel processing▪ Collaborative cloud platform▪ Best-in-class data security |
|---|---|



A portfolio of AI-powered digital assays to support pathologists

imageDx QC

Integrated AI-powered image QC tools automatically assess focus, tissue and slide artifacts, and staining color profiles at scale.

imageDx TUMOR

AI-powered segmentation increases the accuracy and reproducibility of automated scoring in oncology. Automated scoring from H&E stained whole slide images.

imageDx IHC

AI-based cell segmentation and IHC qualification increases accuracy over traditional image analysis techniques - >250 optimized IHC protocols.

imageDx HIGH-PLEX IF

Automated cell-by-cell quantitative multiplex IF analysis paired with optimized protocols.

imageDx NASH

Co-developed with a team of leading US liver pathologists to automate NASH scoring in the cloud.



Predictive AI reveals novel insights that can't be seen by eye

PREDICTIVE AI MODELS

Reveal's proprietary pipeline architecture accelerates model development, reduces costs and timelines, and facilitates regulatory oversight and traceability.

MULTI-OMIC DATA INTEGRATION

Integrate multi-omic data sets to reveal novel insights: genomic, proteomic, patient outcomes, biomarker data, blood chemistry and more.

STRATIFY PATIENT GROUPS

AI/ML-powered digital assays generate standardized, quantitative pathology endpoints to support research, clinical trials, and other large data sets.

**EXPERIENCE DATA POWERED PATHOLOGY
CONTACT US TO REQUEST A DEMO**

SS_Reveal_2022-03-09



ABOUT CELLCARTA

Leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. The company operates globally with 11 facilities located in Canada, USA, Belgium, Australia and China.

www.cellcarta.com
info@cellcarta.com
Toll Free: + 1 877 776 3443

HEADQUARTERS

201 President Kennedy Ave., Suite 3900
Montreal, Quebec, Canada H2X 3Y7
Phone: + 1 514 360 3600